-+ 0.00%
-+ 0.00%
-+ 0.00%

Alpha Tau Medical nine-month 2026 net loss more than triples to $98.9 million

PUBT·11/19/2026 21:03:41
Listen to the news
Alpha Tau Medical nine-month 2026 net loss more than triples to $98.9 million
  • Alpha Tau Medical’s net loss more than tripled to $98.9 million for the nine months ended September 30, 2026, versus a year earlier.
  • Net financial expenses rose to $58.5 million, primarily due to warrants liability remeasurement.
  • Cash, cash equivalents, short-term deposits and restricted deposits increased 30% to $99.8 million at September 30, 2026, from December 31, 2025.
  • The REGAIN recurrent glioblastoma trial achieved a 100% objective response rate among six evaluable patients, including five complete responses.
  • Top-line results from the pivotal ReSTART recurrent skin cancer trial are expected in Q1 2027, followed by a potential FDA submission.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alpha Tau Medical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-122234), on November 19, 2026, and is solely responsible for the information contained therein.